Bedrijfsoverzicht
Anika Therapeutics, Inc. is a specialized entity within the healthcare sector that focuses on early intervention orthopedics across the United States, Europe, and international markets. The company operates specifically within the drug manufacturing industry, specializing in specialty and generic pharmaceuticals, which positions it to develop targeted therapeutic solutions for musculoskeletal conditions. Its primary operational scale is reflected in a market capitalization of $212.86M and an annual revenue of $112.82M, supported by a workforce of 235 employees. These financial metrics indicate that the company functions as a mid-sized player in the orthopedic pain management landscape, specifically utilizing its portfolio of osteoarthritis (OA) products and services, such as Monovisc and Orthovisc, to serve a niche but established segment of the medical market.
Financiële gezondheid
The company generated revenue of $112.82M over the trailing twelve months, while reporting a net income of $-9,979,000 and an EBITDA of $-5,471,000. The significant negative net income relative to the positive revenue figure reveals a substantial cost structure burden, where operating expenses and taxes exceed the gross profit generated from sales. Despite the negative earnings, the company maintains a positive free cash flow of $13.28M, which provides essential financial flexibility to fund ongoing research and development or operational needs without immediate reliance on external financing. Profitability analysis shows a gross margin of 56.6%, indicating efficient production and pricing of its core products, contrasted by a low operating margin of 2.1% and a negative profit margin of -9.6%, which highlights high overhead costs eroding bottom-line profitability. On the balance sheet, the company holds $57.48M in cash against $26.25M in debt, supported by a conservative debt-to-equity ratio of 18.30. This liquidity position is further reinforced by a current ratio of 4.72, suggesting that the firm possesses more than four times the current assets necessary to cover its short-term liabilities. However, the return on equity stands at -6.7% and the return on assets is -3.5%, metrics that collectively reveal that management effectiveness is currently challenged by the company's inability to generate positive returns on its capital base.
Waarderingsbeoordeling
The valuation profile of Anika Therapeutics is characterized by a trailing P/E ratio that is N/A due to negative earnings, while the forward P/E is calculated at 36.90. The absence of a trailing P/E and the presence of a high forward P/E imply that the market is pricing in a significant expected earnings trajectory that has not yet been realized in historical performance. Additionally, the price-to-book ratio is 1.43, indicating that the market values the company at a 43% premium over its net asset value, reflecting potential intangible assets or future growth expectations despite current losses. Alternative valuation metrics further contextualize the stock's pricing, as the price-to-sales ratio stands at 1.89 and the EV/EBITDA is -30.45, suggesting that traditional multiple-based comparisons are skewed by the company's current lack of profitability. In terms of trading range, the stock has fluctuated between a 52-week high of $15.48 and a 52-week low of $7.87, currently trading within a range that reflects significant volatility relative to its recent history. The beta value of 0.28 indicates that the stock's price volatility is substantially lower than that of the broader market, suggesting it may behave more like a defensive asset in certain market conditions.
Growth & Income
The revenue growth year-over-year is 0.0%, and the earnings growth year-over-year is N/A, reflecting a period of stability in sales volume but an absence of earnings expansion. Since the earnings growth is not applicable due to negative net income, the company's earnings are not growing faster than revenue, as both metrics are constrained by the current operational headwinds. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend payout indicates that the company retains all earnings and reinvests capital back into the business rather than distributing returns to shareholders. Consequently, the overall growth and income profile for Anika Therapeutics is defined by a reliance on organic business development and potential future profitability to drive shareholder value, rather than current cash flow distributions or rapid revenue expansion.